Navigation Links
Intarcia Therapeutics, Inc. Commences Enrollment of ITCA 650 Phase 2 Study in Type 2 Diabetes
Date:9/17/2009

tions of Byetta to ITCA 650. The study will provide important information to support dose selection for ITCA 650 phase 3 evaluation, anticipated to begin in the second half of 2010. Additionally, this phase 2 study will provide important insights into future clinical use of ITCA 650 with respect to switching patients from injectable Byetta therapy to ITCA 650.

"We have received strong interest in the ITCA 650 program since the late-breaker presentation of preliminary phase 1b study results at the American Diabetes Association Conference in June" said K. Alice Leung, President and CEO of Intarcia. "We intend to select a commercial partner for ITCA 650 prior to the start of phase 3 in the second half of 2010."

About ITCA 650

ITCA 650 therapy for type 2 diabetes consists of DUROS continuous delivery of exenatide. The DUROS delivery technology comprises the proprietary DUROS device, a matchstick-size miniature osmotic pump that is inserted subcutaneously to provide continuous and consistent drug therapy, and proprietary formulation technology that maintains stability of therapeutic proteins and peptides at human body temperature for extended periods of time. The DUROS technology can deliver up to a full year of therapy from a single ITCA 650 insertion. Unlike other extended delivery technologies, such as polymers or albumin fusions, DUROS delivery allows for steady state drug delivery upon insertion and near immediate withdrawal of therapy to manage side effects, if required. Exenatide, the active agent in ITCA 650, has been approved in the US, Europe and many other markets and is currently marketed as a twice-daily self-injection therapy for type 2 diabetes.

About Intarcia

Intarcia Therapeutics, Inc. is a biopharmaceutical company developing therapies to ensure enhanced treatment outcome by optimizing patient adherence and improving the convenience and tolerability of drug therapies. Intarcia's
'/>"/>

SOURCE Intarcia Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Intarcia Therapeutics, Inc. Announces Appointment of Kenneth Luskey, M.D. as Vice President, Clinical Research
2. Intarcia Therapeutics, Inc. Announces Acceptance of ITCA 650 Phase 1b Study for Late-Breaker Presentation at the American Diabetes Association 69th Scientific Sessions
3. Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
6. ARYx Therapeutics, Inc. Files Registration Statement for Initial Public Offering
7. Nile Therapeutics, Inc. Adds to Executive Management Team
8. Cell Therapeutics, Inc. (CTI) Receives SPA Approval from FDA and Launches Gender-Specific Phase III Trial for Advanced Non-Small Cell Lung Cancer
9. Founder of ILEX Oncology and Triton Biosciences, Richard Love, Joins Board of Directors of Cell Therapeutics, Inc. (CTI)
10. Cell Therapeutics, Inc. (CTI) Announces 2007 Annual Shareholders Meeting Results
11. Northwest Biotherapeutics, Inc. Announces Appointment of Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... Express Diagnostics Int’l, Inc. (EDI) , ... pleased to announce a sponsorship agreement with Erebus Motorsport ... distributor of DrugCheck® onsite testing devices, manufactured by EDI. ... Austin 400 May 17-19 in Austin, Texas. , Royal ... each car of the Erebus Motorsport team displaying the ...
(Date:5/22/2013)... Chester, PA (PRWEB) May 22, 2013 ... company as Fermentation Manager. Mr. McErlean has an ... variety of leadership positions throughout his career. ... “We are very pleased to have Mike join our ... newly installed large scale fermentation and downstream ...
(Date:5/22/2013)... 22, 2013 The ability to ... the information they encode. There are now a ... sequencing of ribosome protected fragments) that dramatically expand ... Keynote speakers include Dr. Jonathan Weissman, an Investigator ... Howard Hughes Medical Institute, who will present recent ...
(Date:5/21/2013)... 22, 2013 First patients dosed ... glycopyrronium bromide designed using Prosonix, particle engineering platform ... portfolio of inhaled Respiratory Medicines by Design , ... that will assess its effect on lung function and ... with moderate to severe chronic obstructive pulmonary disease (COPD). ...
Breaking Biology Technology:Australian Distributor of Express Diagnostics Signs Sponsorship Agreement with V8 Supercar Team 2Envera Appoints Michael McErlean Fermentation Manager 2Monitoring Protein Synthesis One Codon at a Time Through Ribosome Profiling, a Webinar Hosted by Xtalks 2Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 2Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 3Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 4
... (OTC Bulletin Board: BSTC), a biopharmaceutical company,developing first ... Thomas Wegman, will present at the upcoming Piper,Jaffray ... 2, 2008, at,4:30pm ET at the New York ... A live webcast ...
... Par Pharmaceutical Companies, Inc. (NYSE: PRX ) ... District of New Jersey last night granted AstraZeneca Pharmaceuticals, ... of Teva,s generic Pulmicort Respules(R) (budesonide inhaled solution). ... agreed and that it too would halt all sales ...
... Inc.,(Nasdaq: NBIX ) announced today that Kevin ... be presenting at the 20th,Annual Piper Jaffray Health Care ... The live "fireside chat" presentation takes place ... /10:30 a.m. Pacific Time (PT). The,presentation will be simultaneously ...
Cached Biology Technology:Par Pharmaceutical Halts Shipment of Budesonide Inhalation Suspension 2
(Date:5/21/2013)... at USC have found that a class of pharmaceuticals ... , The drugs, known as "TSPO ligands," are ... looked at the effects of TSPO ligand in young ... and in aged mice when pathology was quite severe," ... School of Gerontology. "TSPO ligand reduced measures of pathology ...
(Date:5/21/2013)... Michigan Water Center today awarded 12 research grants, ... and protection efforts. , The two-year grants of ... efforts to track the remediation of harmful algae ... non-native weedy plant invasions; study chromosomal damage in ... restoration activities. , The grants were awarded to ...
(Date:5/21/2013)... an uphill battle? Try staying fit in space, where ... and bone. , That,s the challenge a group of ... three-year, $1.2 million grant from NASA. Their goal is ... missions. , "You could give astronauts the best exercise ... to stick to it, it isn,t going to help," ...
Breaking Biology News(10 mins):Drugs found to both prevent and treat Alzheimer's disease in mice 2U-M Water Center awards $570K in Great Lakes restoration grants 2U-M Water Center awards $570K in Great Lakes restoration grants 3U-M Water Center awards $570K in Great Lakes restoration grants 4Fueling fitness on the final frontier 2
... risky for some,breastfeeding mothers, according to researchers at The ... Children (SickKids) in Toronto.,Lead author Dr. Gideon Koren published ... which suggests that the codeine used in some ... fatal results for infants when ingested by some breastfeeding ...
... NH Embracing the belief that an interdisciplinary and ... advancing science and influencing policy, a group of experts ... how mercury moves through the marine ecosystem and into ... Metals Research Program convened the group of 43 leading ...
... protect people from heart attacks. But to do that they ... Earlier this year, a team led by William Maisel at ... be used to modify wireless communications from a pacemaker ( ... these signals to monitor and adjust the implanted device, but ...
Cached Biology News:Codeine not safe for all breastfeeding moms and their babies 2Dartmouth workshop sets research agenda for environmental mercury 2How to stop a new type of heart attack 2
...
... The CopyControl™ PCR Cloning Kits are designed to ... ensure that all PCR products, regardless of sequence ... All PCR products including those that are difficult ... that may be unstable or code for potentially ...
... 40 reactions. Optimized for the rapid ... products with blunt or sticky ends.Replaces ... consistently better signal-to-noise ratios and as ... generated by proof-reading thermostable polymerases are ...
Antibodies were affinity purified using epitopes specific to XLF immobilized on solid support....
Biology Products: